Developing a New qPCR‐Based System for Screening Mutation
Source abstract
Abstract
Abstract An accurate genotyping analysis is one of the critical prerequisites for lung cancer targeted therapy. Here, a quantitative polymerase chain reaction (qPCR)‐based mutation detection system, mutation‐selected amplification‐specific system PCR (MASS‐PCR), is developed. The specific primers and probes used in MASS‐PCR exactly match with the mutant sequence that only allows mutant gene to emit the fluorescence peak. To determine the sensitivity of MASS‐PCR, 717 lung cancer specimens, 61 formalin‐fixed paraffin‐embedded (FFPE) tissues, and 656 fresh reaction tissues are collected and undergo mutation detection of lung cancer driver genes (EGFR, KRAS, BRAF, HER2, MET, ALK, and ROS1). These samples are divided into two groups. Mutations in Group I, which has 631 fresh reaction tissues, are analyzed by MASS‐PCR and the amplification refractory mutation system PCR (ARMS‐PCR). While group II samples, 25 fresh reaction tissues and 61 FFPE tissues, are screened through MASS‐PCR and next‐generation sequencing (NGS). All results are verified by direct sequencing. MASS‐PCR shows high consistency with ARMS‐PCR (kappa value > 0.733) and NGS (kappa value = 0.79) (P < 0.001). For the samples with inconsistent MASS‐PCR and ARMS‐PCR results, DS results more likely support the MASS‐PCR results. These data suggest that MASS‐PCR is a convenient, accurate, and economical method for the detection of lung cancer driver gene mutations in clinical practice.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Genomics and Phylogenetic Studies · RNA and protein synthesis mechanisms · Molecular Biology Techniques and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Thoracic Surgery Shanghai Pulmonary Hospital Tongji University Shanghai 200433 China
Department of Thoracic Surgery and Minimally Invasive Thoracic Surgery Unit (UCTMI) Coruña University Hospital Coruña 15706 Spain
Shanghai Tongshu Biotechnology Co., Ltd Shanghai 200444 China
Institute for Advanced Study Tongji University Shanghai 200430 China
Funding
National Natural Science Foundation of China · Foundation of Shanghai Municipal Commission of Health and Family Planning
References (17)
Show source-provided references
1. 10.1093/annonc/mdv18710.1093/annonc/mdv187 ↗
2. 10.1016/S1470-2045(14)71207-010.1016/S1470-2045(14)71207-0 ↗
3. 10.1056/NEJMoa04093810.1056/NEJMoa040938 ↗
4. 10.21037/atm.2017.04.1210.21037/atm.2017.04.12 ↗
5. 10.1038/ng.43710.1038/ng.437 ↗
6. Liu L. · J. Biomed. Biotechnol. · 2012 · 251364
7. 10.1073/pnas.74.12.546310.1073/pnas.74.12.5463 ↗
8. 10.2144/00011277610.2144/000112776 ↗
9. Feng Q. · OncoTargets Ther. · 2017 · 8 · 5955210.18632/oncotarget.19110 ↗
10. 10.1089/gtmb.2015.022910.1089/gtmb.2015.0229 ↗
11. 10.1038/nm170810.1038/nm1708 ↗
12. 10.1016/S1525-1578(10)60571-510.1016/S1525-1578(10)60571-5 ↗
13. 10.1007/s12032-014-0926-310.1007/s12032-014-0926-3 ↗
14. 10.1111/j.1471-8286.2007.01804.x10.1111/j.1471-8286.2007.01804.x ↗
15. 10.1016/j.ymeth.2010.01.00310.1016/j.ymeth.2010.01.003 ↗
16. 10.1128/JCM.00803-1410.1128/JCM.00803-14 ↗
17. 10.1038/nrg.2016.4910.1038/nrg.2016.49 ↗